MEDBOT™

Shanghai MicroPort MedBot (Group) Co., Ltd.
上 海 微 创 医 疗 机 器 人（集 团）股 份 有 限 公 司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

POSITIVE PROFIT ALERT

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") hereby informs the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the preliminary assessment and analysis of the unaudited consolidated management accounts of the Company for the six months ended 30 June 2026 (the "**Reporting Period**") and other information currently available to the Board, the Board expects that the Company will turn from a net loss to recording a net profit during the Reporting Period, and the net profit is expected to be approximately RMB28 million to RMB40 million, as compared with a net loss of the Company of RMB115 million for the six months ended 30 June 2025. This marks the first time the Company has achieved semi-annual profitability.

The Company's turnaround from net loss to net profit during the Reporting Period was mainly due to the following factors:

1. Substantial Growth in Revenue — During the Reporting Period, the Group recorded a year-on-year revenue increase of approximately 200% to 230%. Toumai Laparoscopic Surgical Robot delivered robust growth in both domestic and overseas markets with a notable expansion in sales volume. In particular, Toumai's revenue from overseas markets grew by more than 450% year-on-year. Such growth was driven by widespread recognition of the product's technical competitiveness and clinical performance, coupled with the Group's effective synergy with MicroPort's overseas sales channels and resources, and both the depth and breadth of market coverage were expanded simultaneously.

2. Significant Improvement of Gross Profit Margin — During the Reporting Period, the Company's overall gross profit margin improved by more than 15 percentage points compared to the same period last year. This improvement was driven, on the one hand, by the dilution effect of fixed costs resulting from the expansion of production scale; on the other hand, the continuous optimisation of production processes led to an effective reduction in direct labour costs, while the phased implementation of cost-saving processes also contributed to a gradual reduction in material costs. Meanwhile, the continuous optimisation of product portfolio, particularly the rapid increase of revenue from high-margin consumables, has also driven the gross profit margin to steadily increase.

3. Continuous Optimisation of Expense Control — During the Reporting Period, the Company continued to achieve positive results in expense control and resource allocation. The ratio of operating expenses to revenue decreased significantly, further improving the overall operational efficiency.

In summary, the combined effects of revenue growth, improvement of gross profit margin and optimisation of expense control laid a solid foundation for the Group to achieve profitability for the first time for the Reporting Period.

As at the date of this announcement, the Company is still preparing and finalising its interim results for the Reporting Period. The figures set out in this announcement are based solely on a preliminary assessment and analysis of the unaudited consolidated management accounts of the Group for the Reporting Period provided to the Board as at the date of this announcement and other information currently available to the Board. Such figures are subject to finalisation and other potential adjustments (if any), and have not been audited or confirmed by the auditors of the Company or the Audit Committee of the Company.

The Company will publish the interim results announcement for the Reporting Period on or before 31 August 2026. Shareholders and potential investors are advised to read the interim results announcement carefully upon its publication.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Dr. Zhaohua Chang
Chairman

Shanghai, China, 22 July 2026

As at the date of this announcement, the executive directors are Dr. Chao He and Mr. Yu Liu, the non-executive directors are Dr. Zhaohua Chang, Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Mr. Chen Chen and Ms. Min Liang, and the independent non-executive directors are Dr. Guoen Liu, Mr. Jonathan H. Chou, Mr. Haisong Yao and Mr. Wai Man Chung.